TuHURA Biosciences (NASDAQ:HURA) Trading 2.8% Higher – What’s Next?

TuHURA Biosciences, Inc. (NASDAQ:HURA)’s share price was up 2.8% during trading on Thursday . The company traded as high as $2.66 and last traded at $2.59. Approximately 397,707 shares were traded during mid-day trading, a decline of 21% from the average session volume of 500,792 shares. The stock had previously closed at $2.52.

Wall Street Analysts Forecast Growth

HURA has been the topic of a number of analyst reports. Citigroup assumed coverage on TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating on the stock. Rodman & Renshaw started coverage on TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating for the company. Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, May 31st. Citizens Jmp started coverage on TuHURA Biosciences in a research report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, TuHURA Biosciences has a consensus rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Trading Up 2.8%

The company’s fifty day simple moving average is $2.40 and its 200 day simple moving average is $1.65. The stock has a market capitalization of $164.93 million, a P/E ratio of -4.25 and a beta of 0.01.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Equities research analysts predict that TuHURA Biosciences, Inc. will post -0.56 earnings per share for the current year.

Hedge Funds Weigh In On TuHURA Biosciences

A number of institutional investors have recently added to or reduced their stakes in the business. Merck & Co. Inc. raised its holdings in shares of TuHURA Biosciences by 39.4% in the 1st quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock valued at $35,000 after acquiring an additional 5,495 shares in the last quarter. PFG Investments LLC grew its holdings in shares of TuHURA Biosciences by 39.4% during the first quarter. PFG Investments LLC now owns 32,630 shares of the company’s stock worth $58,000 after purchasing an additional 9,219 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of TuHURA Biosciences during the third quarter worth about $26,000. JPMorgan Chase & Co. bought a new position in shares of TuHURA Biosciences in the second quarter worth approximately $27,000. Finally, Invesco Ltd. purchased a new stake in TuHURA Biosciences in the second quarter valued at approximately $30,000. 0.62% of the stock is currently owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.